Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
265 Leser
Artikel bewerten:
(1)

BC Platforms Partners with Genomenon to Boost Rare Disease Diagnostics and Research

Finanznachrichten News

Genomenon's 'Mastermind' AI-driven Genomic Search Engine combined with both BC Platforms' Personalized Medicine BC|GENOME and Research and Discovery BC|INSIGHT Platforms

ZURICH and BOSTON, Feb. 23, 2021 /PRNewswire/ -- BC Platforms, a global leader in healthcare data management, analytics and access announced that it has entered a collaboration with AI-driven genomics company, Genomenon (Ann Arbor, Michigan USA). The partnership is focused on two fronts. Firstly, with the vision to advance clinical genomics, Genomenon's Mastermind Genomic Search Engine will be integrated into BC Platforms' genomic analysis and interpretation platform BC|GENOME. On the research side, Mastermind will also be integrated into BC Platforms' research platform BC|INSIGHT to facilitate complex genomic research by simplifying genomic data annotations and thus enabling AI/ML applications.

Genomenon's Mastermind uses AI-driven genomics to accelerate variant interpretation, providing immediate insight into the full text of millions of scientific articles. Mastermind identifies every genomic association supported by the medical evidence, drawing informative connections between genes, variants, copy number variants (CNVs), diseases, phenotypes, therapies, and categorical keywords to inform both clinical care and drug discovery. By allowing users to find, connect, explore, and understand the links between genomic concepts of interest, Mastermind elevates the efficiency and accuracy of the clinical decision-making process.

Personalized medicine platform powered by BC|GENOME is a highly interoperable and configurable genomics platform for clinical grade genomic data production, analysis and interpretation. Combining automation with a glass box approach, it is the solution of choice for leading healthcare organisations and genomics labs globally.

Discovery and research platform powered by BC|INSIGHT is a highly scalable research data management solution for managing healthcare data, conducting studies as well as enabling research collaborations by proving a trusted research environment. Through its built-in patient data logic, ability to handle all data types and robust access management, the solution has been a preferred platform for over 20 years for a wide range of research environments from single cohort to population scale.

Tero Silvola, CEO of BC Platforms, said, "We are delighted to be working with Genomenon, and enhancing the value of its outstanding 'Mastermind' Genomic Search Engine to healthcare and research collaborators. Mastermind is the only one of its kind, delivering insight into the full text of genomic literature in the blink of an eye. Genomenon is a natural partner for us as both companies are passionate about powering evidence-based genomics. This is about super-charging data-driven decision-making in healthcare."

Mike Klein, CEO of Genomenon, said, "We look forward to this collaboration and share BC Platforms' commitment to deliver the most comprehensive source of genomic evidence to researchers and clinicians working on the frontiers of medical science."

About BC Platforms

BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between personalized care and research discoveries, leveraging latest science, deep technical expertise, strategic partnerships, and harmonized, diverse data collections. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. Additionally, BC Platforms has developed a Global Data Partner Network BCRQUEST.com, which provides genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms' vision is to build the world's leading analytics platform for healthcare and industry, providing access to diverse genomic and clinical data and samples from more than 5 million subjects, consolidated from a global network of Data Partners.

Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, and industry partners. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and presence in London, Boston and in Singapore. For more information, please visit www.bcplatforms.com or follow us on Linkedin @BC Platforms.

About Genomenon

Genomenon is an AI-driven genomics company that organizes the world's genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.

Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

https://www.genomenon.com/

Contact information:

Tero Silvola
BC Platforms AG
Tero.silvola@bcplatforms.com

Katja Stout
Scius Communications
katja@sciuscommunications.com

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.